KEI Comments Regarding NIH Exclusive License to Retargeted Therapeutics for Cancer Treatment

Update: The NIH sent a response to our comments, available here. The response fails to address the glaring lack of information available regarding Retargeted Therapeutics. On June 8, 2020, Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT)… Continue Reading

Joint Comments by KEI, UACT, Social Security Watch and Health Gap on the proposed NIH Exclusive License in CAR Therapy to Lyell Immunopharma (and NIH Response)

(UPDATE: As noted in the comments below, the NIH provided a response to the joint comments submitted on September 5, 2019, well in advance of the close of the comment period on September 15, 2019) On September 19, 2019, Knowledge… Continue Reading